Asulacrine, also known as CI-921, an inhibitor of topoisomerase II, participated in clinical trials phase II for the treatment of cancer. In spite of the positive and promising results, this drug showed the toxicity, phlebitis that blocks its implementation in the future.

Atiprimod is an oral azaspirane which was initially developed by Smith Kline and French Laboratories for treating rheumatoid arthritis (discontinued in phase I). Due to its anti-inflammatory, antineoplastic, and antiangiogenic properties, the drug was tested in patients with Neuroendocrine Carcinoma and Multiple Myeloma and reached phase II (discontinued). In vitro studies revealed that atiprimod exerts its action by inhibiting the phosphorylation of signal transducer and activator of transcription 3 (STAT3), blocking the signalling pathways of interleukin-6 and vascular endothelial growth factor (VEGF) and downregulating the anti-apoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, thereby inhibiting cell proliferation, inducing cell cycle arrest, and inducing apoptosis.

Anazolene Sodium is a diagnostic die used for blood volume and cardiac output determination.

Brivanib is a pyrrolotriazine-based compound and an inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) with potential antineoplastic activity. It specifically targets and strongly binds to human VEGFR-2, a tyrosine kinase receptor and pro-angiogenic growth factor expressed almost exclusively on vascular endothelial cells. Blockade of VEGFR-2 by this agent may lead to an inhibition of VEGF-stimulated endothelial cell migration and proliferation, thereby inhibiting tumor angiogenesis. Brivanib has a moderate potency compared to VEGFR-2 against VEGFR-1 and FGFR-1 as well. Brivanib is suggested to be efficient in treatment of hepatocellular carcinoma (HCC). As first-line and as second-line therapy brivanib demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, unresectable HCC in phase II clinical trials. On 3 march 2011, orphan designation was granted by the European Commission to Bristol-Myers Squibb for brivanib alaninate for the treatment of hepatocellular carcinoma.[

Lonaprofen is an analgesic, antipyretic and anti-inflammatory agent.

Lometraline is a tranquillizer and anti-parkinsonian drug. It was developed as an antidepressant agent. Lometraline is a congener of popular antidepressant (+)-sertraline.

Lofemizole is a non-steroidal anti-inflammatory drug. Lofemizole has proved to possess an interesting antiphlogistic activity in both animals and humans, associated with a favorable gastric and systemic tolerability.

Benethamine penicillin is a medium-long-acting insoluble penicillin salt. After a single injection, this salt acts and bacteriostatic level of penicillin is maintained in the blood for three to six days.

Limazocic is a cyclic disulfide compound newly synthesized as a hepatoprotective agent. It has a protective effect against both chronic liver injuries induced by carbon tetrachloride (CCL) and swine serum and several chemically induced acute liver injuries. The inhibitory effects of limazocic on immunologically induced liver injuries in mice have also been demonstrated and furthermore, limazocic has been shown to have immunomodulatory effects such as induction of cytotoxic cell activities and modulation of interleukin-2 and interferon-gamma production. Limazocic had a markedly inhibitory effect on ANIT-induced intrahepatic cholestasis in rats. Limazocic suppresses VEGF production and reduces vascular leakage and the growth of mouse experimental choroidal neovascularization.